KORA SAUDE (KRSA3) Main Indicators
Basic Data - KRSA3
| Company | KORA SAUDE |
| Corporate Name | KORA SAÚDE PARTICIPAÇÕES S.A |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Holding de instituições não financeiras com fim a prestação de serviços de atenção a saúde humana. limpeza. planos de saúde. bem como outras atividades secundárias como aluguel de imóveis. |
| Share | KRSA3 |
| Quote Date | 09/18/2024 |
| Share Type | ON |
| Last Closing | R$ 0.50 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 256.30 thousand |
| Last Statement | ITR - 06/30/2024 |
| Sector | Saúde |
| Subsector | Serv.Méd.Hospit..Análises e Diagnósticos |
| Segment | Serv.Méd.Hospit..Análises e Diagnósticos |
| Participation Indexes | - |
| Updated 09/19/2024 | |
Relative Prices - KRSA3
| Price/Earnings | -3.22 |
| Price/SBV | 0.41 |
| Price/Net Sales | 0.17 |
| Price/CFO | 2.83 |
| Price/FCF | 5.98 |
| Price/Total Assets | 0.08 |
| Price/EBIT | 1.26 |
| Price/Working Capital | 0.72 |
| Price/NCAV | -0.12 |
| EV/EBIT | 9.69 |
| EV/EBITDA | 6.29 |
| EV/Net Sales | 1.30 |
| EV/CFO | 21.73 |
| EV/FCF | 45.93 |
| EV/Total Assets | 0.62 |
| Company Market Cap | R$ 386.67 M |
| Enterprise Value | R$ 2.97 B |
| Current Financial Statement Date | 06/30/2024 |
| Current Share Price | R$ 0.50 |
| Share Price Date | 09/18/2024 |
| Dividend Yield | 0.00% |
| Updated 09/19/2024 | |
Income Statement - KRSA3
| Net Revenue | R$ 2.29 B |
| Gross Result | R$ 461.60 M |
| EBIT | R$ 306.60 M |
| Depreciation and Amortization | - R$ 165.82 M |
| EBITDA | R$ 472.42 M |
| Net Profit | - R$ 120.01 M |
| Net Profit/Share | - R$ 0.16 |
| Updated 08/12/2024 | |
| Net Revenue | R$ 582.57 M |
| Gross Result | R$ 115.84 M |
| EBIT | R$ 70.92 M |
| Depreciation and Amortization | - R$ 37.05 M |
| EBITDA | R$ 107.97 M |
| Net Profit | - R$ 27.94 M |
| Profit/Share | - R$ 0.04 |
| Updated 08/12/2024 | |
Price and Volume Behavior - KRSA3
| Lowest Price 52 weeks | R$ 0.50 |
| Highest Price 52 weeks | R$ 1.40 |
| Variation 2024 | -60.94% |
| Variation 1 year | -48.98% |
| Variation 2 years(total) | -81.62% |
| Variation 2 years(yearly) | -56.98% |
| Variation 3 years(total) | -93.51% |
| Variation 3 years(yearly) | -59.74% |
| Variation 4 years(total) | - |
| Variation 4 years(yearly) | - |
| Variation 5 years(total) | - |
| Variation 5 years(yearly) | - |
| Average Daily Volume (3 months) | R$ 392.52 thousand |
| Updated 09/19/2024 | |
Returns and Margins - KRSA3
| Return on Initial Tangible Capital | 9.04% |
| Return on Initial Invested Capital | 6.13% |
| Pre-Tax Return on Initial Tangible Capital | 13.70% |
| Pre-Tax Return on Initial Invested Capital | 9.29% |
| Return on Initial Shareholder´s Equity | -11.42% |
| Return on Initial Asset | -2.52% |
| Gross Margin | 20.16% |
| Net Margin | -5.24% |
| EBIT Margin | 13.39% |
| EBITDA Margin | 20.64% |
| Initial Asset Turnover | 0.48 |
| Financial Leverage | 5.10 |
| Liabilities/Net Worth | 4.10 |
| Net Debt/EBITDA | 5.47 |
| Updated 08/12/2024 | |
Balance Sheet - KRSA3
| Cash and Cash Equivalents | R$ 228.03 M |
| Total Assets | R$ 4.76 B |
| Short-Term Debt | R$ 372.61 M |
| Long-Term Debt | R$ 2.44 B |
| Gross Debt | R$ 2.81 B |
| Net Debt | R$ 2.59 B |
| Shareholder´s Equity | R$ 932.96 M |
| Share Book Value | R$ 1.21 |
| Common Shares | 773,348,000 |
| Preferred Shares | 0 |
| Total | 773,348,000 |
| Common Shares in Treasury | 4,806,000 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 4,806,000 |
| Common Shares (Except Treasury) | 768,542,000 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 768,542,000 |
| Updated 08/12/2024 | |
Cash Flow - KRSA3
| Operating Cash Flow | R$ 136.79 M |
| Cash Flow from Investments | - R$ 87.65 M |
| Financing Cash Flow | - R$ 11.12 M |
| Increase (Reduction) in Cash and Equivalents | R$ 38.02 M |
| Updated 08/12/2024 | |
| Operating Cash Flow | - R$ 15.04 M |
| Cash Flow from Investments | R$ 1.14 M |
| Financing Cash Flow | R$ 26.69 M |
| Increase (Reduction) in Cash and Equivalents | R$ 12.78 M |
| Updated 08/12/2024 | |
Experimental - KRSA3
| CAPEX 3 months | R$ 1.14 M |
| Free Cash Flow 3 months | - R$ 13.91 M |
| CAPEX 12 months | - R$ 72.08 M |
| Free Cash Flow 12 months | R$ 64.71 M |
| Updated 08/12/2024 | |